ClearPoint Neuro ( (CLPT) ) just unveiled an announcement.
On February 26, 2025, ClearPoint Neuro announced its financial results for the fourth quarter and full year of 2024, highlighting a record revenue of $31.4 million for the year, marking a 31% increase over 2023. The company reduced its operational cash burn by 35% and activated 25 new global centers in 2024. ClearPoint Neuro aims to expand its global footprint and accelerate the launch of new products, focusing on supporting BioPharma partners in the commercialization of cell and gene therapies. The company anticipates revenue growth between 15% and 31% for 2025.
More about ClearPoint Neuro
ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company that provides precise navigation solutions for the brain and spine. The company focuses on drug delivery for neuro disorders and offers products such as the SmartFrame OR platform and ClearPoint Prism Laser Therapy System. ClearPoint Neuro collaborates with BioPharma partners and is involved in clinical trials for cell and gene therapies.
YTD Price Performance: 7.59%
Average Trading Volume: 217,234
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $461.2M
For detailed information about CLPT stock, go to TipRanks’ Stock Analysis page.